You are here

Our science / Clinical Trials / Find a Trial / NCT00505973

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT00505973

Last updated on February 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Ikebukuro, Toshima-ku, 171-0014 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healty Japanese men willing to use a medically acceptable form of contraception.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any significant disease

- Positive urine drug screen

- Increased liver function tests

- Use of prescription drugs.

NCT00505973
Pfizer
Completed
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Schizophrenia
Open Label Extension Study of Bifeprunox
NCT00366171
All Genders
18+
Years
Multiple Sites
Schizophrenia
Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
NCT00781794
All Genders
18+
Years
Multiple Sites
Schizophrenia
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
NCT00567203
All Genders
18+
Years
Multiple Sites
Schizophrenia
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now